This study aimed to compare the levels of IL-2 between breast cancer patients and healthy women, and also compared the levels of IL-2 between HER-2 positive and HER-2 negative, ER/PR positive and ER/PR negative, and among the different malignancy grades of breast cancer patients. This evidence concerns the gene PGR and breast carcinoma.